Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

Official Title

A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo After Complete Resection of Stage IIB/C Melanoma


The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recurrence.

Trial Description

Primary Outcome:

  • Recurrence-Free Survival (RFS)
  • Number of other safety biomarkers
Secondary Outcome:
  • Overall survival (OS)
  • Number of Participants with Serious Adverse Events (SAEs)
  • Number of Participants with Adverse Events (AEs)
  • Distant Metastases-Free Survival (DMFS)
  • Objective Response Rates (ORR)
  • Outcomes on Next-Line therapies (Objective response rate [if applicable], Duration of treatment on next-line therapies, Progression-Free Survival 2)
  • Incidence of change in Vital Signs
  • Incidence of change in Electrocardiograms (ECGs)
  • Incidence of change in biomarkers
  • Incidence of change in clinical laboratory values

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society